Snapshot from Jun 09, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Zoetis Securities Class Action Lawsuit
Regulatory class action lawsuit

Zoetis Securities Class Action Lawsuit

Analysis based on 9 articles · First reported May 28, 2026 · Last updated May 30, 2026

Sentiment
-60
Attention
4
Articles
9
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against Zoetis>>> directly impacts its stock price and investor confidence, as allegations of securities fraud and declining product sales have already led to significant drops in its stock value. The legal proceedings could result in substantial financial penalties for Zoetis>>> and further erode its market capitalization.

Pharmaceuticals Legal Services
Event Summary

A class action lawsuit has been filed against Zoetis>>> Inc. by Robbins Geller Rudman & Dowd LLP>>> on behalf of investors who purchased Zoetis>>> securities between January 14, 2025, and May 6, 2026. The lawsuit alleges that Zoetis>>> and its executives made false and misleading statements and failed to disclose critical information regarding the weakening demand for its key companion animal products, Librela, Simparica Trio, Apoquel, and Cytopoint. These issues include declining veterinarian prescription growth for Librela due to United States — Food and Drug Administration>>> safety warnings, loss of market share for Simparica Trio to competitors, and substantial market share loss for dermatology products Apoquel and Cytopoint. These undisclosed problems led to significant drops in Zoetis>>>' stock price following its quarterly financial results announcements in August 2025, November 2025, February 2026, and May 2026.

Key Actions
100 Robbins Geller Rudman & Dowd LLP filed class action lawsuit Zoetis
90 Zoetis reported financial results
70 United States — Food and Drug Administration issued safety warnings Zoetis
Entities Involved
stock
Zoetis
Zoetis is the defendant in a class action lawsuit alleging securities fraud due to misleading statements and failure to disclose weakening product demand and increased competition, leading to significant stock price declines.
Importance 100 Sentiment -70
priv
Robbins Geller Rudman & Dowd LLP
Robbins Geller Rudman & Dowd LLP is the law firm representing the plaintiffs in the class action lawsuit against Zoetis, seeking to recover losses for investors.
Importance 80 Sentiment 50
oth
City of Ann Arbor Retiree Health Care Benefit Plan and Trust
The City of Ann Arbor Retiree Health Care Benefit Plan and Trust is the named plaintiff in the class action lawsuit against Zoetis.
Importance 40 Sentiment 10
per
Ken Dolitsky
Ken Dolitsky is an attorney at Robbins Geller Rudman & Dowd LLP, involved in the Zoetis class action lawsuit.
Importance 30 Sentiment 20
per
Michael Albert
Michael Albert is an attorney at Robbins Geller Rudman & Dowd LLP, involved in the Zoetis class action lawsuit.
Importance 30 Sentiment 20
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration issued safety warnings concerning neurological complications in dogs related to Zoetis' Librela product, which contributed to weakening demand.
Importance 20 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.